Baidu
map

JACC:对症状稳定的冠脉疾病是采用功能测试还是冠脉造影?

2017-04-10 MedSci MedSci原创

对怀疑有冠脉疾病的稳定患者进行初步评估时,冠状动脉CTA与随后使用他汀类药物、阿司匹林和有创手术比例更高有相关性,治疗成本高于功能测试。

对于疑似冠脉疾病是选择造影还是非侵入性的功能测试会对随后的临床治疗和效果产生影响。近日血管领域权威杂志Journal of the American College of Cardiology发表了一篇研究文章,旨在研究症状稳定的门诊患者初次使用无创心脏检查和随后的用药、有创手术和治疗效果之间的相关性。

共收集了2009至2015年期间参加丹麦全国登记注册的患者,这些患者均初始接受了冠脉CT扫描血管造影(CTA)或功能测试(运动心电图或压力测试)。研究人员对这些患者120天内进一步采取的无创检测、有创手术、用药和医疗费用进行评估。采用调整的Cox比例风险模型分析长期死亡率和心肌梗死(MI)的风险。

共有86,705例患者进行了功能检查(n = 53,744,平均年龄57.4岁,男性49%)或冠状动脉CTA(n = 32,961,平均年龄57.4岁,男性45%),随访时间中位数为3.6年。与功能测试相比,冠状动脉CTA后使用他汀类药物(15.9%vs.9.1%),阿司匹林(12.7%vs. 8.5%),冠状动脉造影(14.7%vs. 10.1%)和经皮冠状动脉介入(3.8% vs. 2.1%)的比例显著升高(P均<0.001)。冠状动脉CTA后的进一步检查、有创手术和药物的平均费用显著升高(995美元对 718美元; P <0.001)。冠状动脉CTA后未调整的死亡率(2.1%vs. 4.0%)和MI住院率(0.8%vs. 1.5%)均低于功能测试(P均 <0.001)。调整后,冠状动脉CTA后全因死亡率与功能测试相当(风险比:0.96;95%CI:0.88-1.05),MI风险低(风险比:0.71;95%CI:0.61-0.82)。

对怀疑有冠脉疾病的稳定患者进行初步评估时,冠状动脉CTA与随后使用他汀类药物、阿司匹林和有创手术比例更高有相关性,治疗成本高于功能测试。冠状动脉CTA与心肌梗死的风险低相关,但CTA和功能测试的全因死亡率相似。

原始出处:
本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853622, encodeId=ae41185362240, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Aug 19 20:30:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189652, encodeId=33e4189652e9, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Apr 22 16:06:59 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325358, encodeId=bb831325358f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447186, encodeId=b30b144e1862f, content=<a href='/topic/show?id=dd2f31009da' target=_blank style='color:#2F92EE;'>#冠脉造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31009, encryptionId=dd2f31009da, topicName=冠脉造影)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=l9h0OhA0BicNC4kpEUl4AeA&s=100&t=1587635346, createdBy=61865326685, createdName=李研东, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494025, encodeId=9e7b149402519, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572978, encodeId=ba6b15e2978b8, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=)]
    2017-08-19 爆笑小医
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853622, encodeId=ae41185362240, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Aug 19 20:30:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189652, encodeId=33e4189652e9, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Apr 22 16:06:59 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325358, encodeId=bb831325358f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447186, encodeId=b30b144e1862f, content=<a href='/topic/show?id=dd2f31009da' target=_blank style='color:#2F92EE;'>#冠脉造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31009, encryptionId=dd2f31009da, topicName=冠脉造影)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=l9h0OhA0BicNC4kpEUl4AeA&s=100&t=1587635346, createdBy=61865326685, createdName=李研东, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494025, encodeId=9e7b149402519, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572978, encodeId=ba6b15e2978b8, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=)]
    2017-04-22 ylzr123

    不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1853622, encodeId=ae41185362240, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Aug 19 20:30:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189652, encodeId=33e4189652e9, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Apr 22 16:06:59 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325358, encodeId=bb831325358f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447186, encodeId=b30b144e1862f, content=<a href='/topic/show?id=dd2f31009da' target=_blank style='color:#2F92EE;'>#冠脉造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31009, encryptionId=dd2f31009da, topicName=冠脉造影)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=l9h0OhA0BicNC4kpEUl4AeA&s=100&t=1587635346, createdBy=61865326685, createdName=李研东, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494025, encodeId=9e7b149402519, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572978, encodeId=ba6b15e2978b8, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853622, encodeId=ae41185362240, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Aug 19 20:30:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189652, encodeId=33e4189652e9, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Apr 22 16:06:59 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325358, encodeId=bb831325358f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447186, encodeId=b30b144e1862f, content=<a href='/topic/show?id=dd2f31009da' target=_blank style='color:#2F92EE;'>#冠脉造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31009, encryptionId=dd2f31009da, topicName=冠脉造影)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=l9h0OhA0BicNC4kpEUl4AeA&s=100&t=1587635346, createdBy=61865326685, createdName=李研东, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494025, encodeId=9e7b149402519, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572978, encodeId=ba6b15e2978b8, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853622, encodeId=ae41185362240, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Aug 19 20:30:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189652, encodeId=33e4189652e9, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Apr 22 16:06:59 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325358, encodeId=bb831325358f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447186, encodeId=b30b144e1862f, content=<a href='/topic/show?id=dd2f31009da' target=_blank style='color:#2F92EE;'>#冠脉造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31009, encryptionId=dd2f31009da, topicName=冠脉造影)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=l9h0OhA0BicNC4kpEUl4AeA&s=100&t=1587635346, createdBy=61865326685, createdName=李研东, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494025, encodeId=9e7b149402519, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572978, encodeId=ba6b15e2978b8, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=)]
    2017-04-12 sodoo
  6. [GetPortalCommentsPageByObjectIdResponse(id=1853622, encodeId=ae41185362240, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Aug 19 20:30:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189652, encodeId=33e4189652e9, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Apr 22 16:06:59 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325358, encodeId=bb831325358f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447186, encodeId=b30b144e1862f, content=<a href='/topic/show?id=dd2f31009da' target=_blank style='color:#2F92EE;'>#冠脉造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31009, encryptionId=dd2f31009da, topicName=冠脉造影)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=l9h0OhA0BicNC4kpEUl4AeA&s=100&t=1587635346, createdBy=61865326685, createdName=李研东, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494025, encodeId=9e7b149402519, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572978, encodeId=ba6b15e2978b8, content=<a href='/topic/show?id=805d3098599' target=_blank style='color:#2F92EE;'>#冠脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30985, encryptionId=805d3098599, topicName=冠脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb3e15794072, createdName=huangshifeng, createdTime=Wed Apr 12 07:30:00 CST 2017, time=2017-04-12, status=1, ipAttribution=)]

相关资讯

冠状动脉疾病或始于童年不健康生活方式

芬兰坦佩雷大学一项长达30多年的跟踪研究显示,冠状动脉疾病的先兆在童年时期就已显现。如果在童年时期不采取健康生活方式,成年后患心血管疾病的风险将明显增高。 1980年,3596名3岁至18岁的受试者参与了这项研究。研究人员分别在1983年、1986年、2001年和2007年对他们进行常规体检和血检。 研究结果表明,童年的饮食和运动习惯与成年期的收缩压、胰岛素及甘油三酯水平密切相关。

SCCT 2014:CT血管造影结果支持2013 ACC/AHA指南

:心血管CT学会(SCCT)2014年会的一项报告表明,对于CT血管造影检出的冠脉闭塞患者,2013 ACC/AHA指南较2004 NCEP ATP III指南更有可能推荐他汀类治疗。 此项研究对来自于ROMICAT I试验的368例中危心血管疾病患者进行了分析,并排除了实际伴有临床急性冠脉综合征以及非40~75岁的患者。研究者依据两项指南对纳入最终分析的252例患者是否适用他汀类治疗进行了评估

Allergy:冠状动脉疾病患者:阿司匹林激发和/或脱敏的合格临床标准

超敏反应即异常的、过高的免疫应答。即机体与抗原性物质在一定条件下相互作用,产生致敏淋巴细胞或特异性抗体,如与再次进入的抗原结合,可导致机体生理功能紊乱和组织损害的免疫病理反应。又称变态反应。2017年3月,发表在《Allergy》的研究旨在在患有冠状动脉疾病的患者中建立阿司匹林的激发或脱敏的合格临床标准。背景:对阿司匹林(ASA)的超敏反应对于患有冠状动脉疾病的受试者构成严重的问题。在这些受试者中

Am J Cardiol:共病和复发性冠脉疾病增多对PCI患者预后无显著影响?

美国一项研究表明,在共病和复发性冠脉疾病日益增多的情况下,经皮冠脉介入(PCI)患者的5年死亡率、重复PCI率和新发病变重复PCI率未出现显著变化。论文12月2日在线发表于《美国心脏病学杂志》(Am J Cardiol)。 此项研究从1999、2004和2006年分别纳入2105、2112和2176例接受PCI治疗的患者,并在共病和治疗演进的环境下评估了冠脉疾病的死亡

Thromb Haemost:SCAD的治疗—替格瑞洛能否取代氯吡格雷?

近期,Thromb Haemost杂志中的一篇报道,对替格瑞洛与氯吡格雷,在稳定性冠脉疾病(SCAD)伴有慢性阻塞性肺疾病(COPD)患者中的疗效进行了对比。这两种药物中,哪种药物对于改善动脉内皮功能的作用更优呢?对于SCAD合并有COPD的患者,其心血管不良事件的发生率较一般人显着提高。慢性炎症、上皮功能失调、氧化应激、及血小板活性(PR)的增强均是不良事件的诱因。46名SCAD合并COPD的患

Eur Heart J:冠脉疾病患者筛查糖尿病 **OGTT

瑞典一项研究表明,在伴有确定性冠脉疾病的患者中,口服糖耐量试验(OGTT)确认的既往未诊断糖尿病患者比率最高,并应作为评估类此患者血糖状况的首选检测。论文2月9日在线发表于《欧洲心脏杂志》(Eur Heart J)。 此项研究共纳入4004例既往无糖尿病病史的冠脉疾病患者,并测定空腹血糖(FPG)、2小时餐后血糖(2hPG)和糖化血红蛋白A1c(HbA1c)。依据ADA和WHO血糖异常标

Baidu
map
Baidu
map
Baidu
map